Flavio Vincenti

Dr. Flavio Vincenti is a Professor of Medicine at the University of California, San Francisco (UCSF) School of Medicine, where he has been on faculty since 1975. He serves in the Department of Medicine's Division of Nephrology and has been actively involved with the transplant service since 1976, focusing on patient care and clinical trials with novel immunosuppression drugs.

Dr. Vincenti completed his medical residency at the University of California, San Francisco School of Medicine, establishing the foundation for his long career in nephrology and transplantation medicine.

Dr. Vincenti's research focuses on advancing kidney transplantation through innovative immunosuppression strategies, particularly costimulation blockade with agents like belatacept. His work spans from basic immunological investigations to large-scale clinical trials that have transformed transplantation practices. He has pioneered research in desensitization protocols for highly sensitized patients, novel biological agents for immunosuppression, and precision medicine approaches to transplantation. His expertise in clinical trial design has made him a leader in evaluating new therapies for transplant recipients, with particular attention to improving long-term outcomes while minimizing complications.

Analysis of Dr. Vincenti's recent publications (2023-2025) reveals a continued emphasis on precision medicine approaches in transplantation, with particular focus on desensitization therapies for highly sensitized kidney transplant candidates, management of complications like neutropenia in transplant recipients, and novel biological agents for immunosuppression. His work bridges basic immunology with clinical applications, often focusing on B-cell and plasma cell biology in the context of transplant rejection, and includes important contributions to race-neutral kidney function assessment and management of post-transplant infections.

Dr. Vincenti has received significant research funding throughout his distinguished career, most notably as Principal Investigator on the AMELIORATE study (NIH U01AI113362, 2014-2024) which applies precision medicine to optimize desensitization with novel biologics or cellular therapies in highly sensitized kidney transplant patients. He was also a Co-Investigator on the General Clinical Research Center grant (NIH M01RR000079, 1974-2009), demonstrating his long-standing commitment to advancing clinical research in transplantation.

Dr. Vincenti has mentored numerous researchers and clinicians in the field of transplantation, contributing significantly to the next generation of transplant specialists. His research has been supported by multiple NIH grants and industry collaborations, reflecting his leadership in clinical trial design and execution in the transplantation field. He has played a pivotal role in numerous landmark studies that have shaped current immunosuppression protocols and clinical practices in kidney transplantation worldwide.

Dr. Vincenti leads research teams focused on translational studies in kidney transplantation, with particular emphasis on immune monitoring, biomarker development, and novel therapeutic approaches for difficult-to-treat transplant patients, especially those who are highly sensitized. His laboratory and clinical research programs work collaboratively to bridge discoveries from bench to bedside, with the ultimate goal of improving long-term outcomes for transplant recipients.